

Norbert Galldiks

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3585553/norbert-galldiks-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213
papers

7,061
citations

44
h-index

77
g-index

232
ext. papers

8,765
ext. citations

4.3
avg, IF

5.93
L-index

#	Paper	IF	Citations
213	Role for neuronal insulin resistance in neurodegenerative diseases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 3100-5	11.5	499
212	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1199-208	1	398
211	Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. <i>Journal of Neuroscience</i> , 2006 , 26, 1343-54	6.6	219
210	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 678-688	40	207
209	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 540-557	8.8	198
208	Advances in neuro-oncology imaging. <i>Nature Reviews Neurology</i> , 2017 , 13, 279-289	15	185
207	¹⁸ F-fluoro-L-thymidine and ¹¹ C-methylmethionine as markers of increased transport and proliferation in brain tumors. <i>Journal of Nuclear Medicine</i> , 2005 , 46, 1948-58	8.9	171
206	Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 685-95	8.8	164
205	Assessment of treatment response in patients with glioblastoma using O-(2- ¹⁸ F-fluoroethyl)-L-tyrosine PET in comparison to MRI. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1048-57	8.9	156
204	Role of O-(2-(¹⁸ F)-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1367-74	8.9	140
203	Response assessment of bevacizumab in patients with recurrent malignant glioma using [¹⁸ F]Fluoroethyl-L-tyrosine PET in comparison to MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 22-33	8.8	136
202	Diagnostic performance of ¹⁸ F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 229-35	8.9	134
201	From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?. <i>Neuro-Oncology</i> , 2015 , 17, 1434-44	1	116
200	Use of ¹¹ C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 516-24	8.8	116
199	The use of dynamic O-(2- ¹⁸ F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. <i>Neuro-Oncology</i> , 2015 , 17, 1293-300	1	100
198	PET imaging in patients with meningioma-report of the RANO/PET Group. <i>Neuro-Oncology</i> , 2017 , 19, 1576-1587	1	97
197	Role of O-(2- ¹⁸ F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 2046-54	8.9	94

196	Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 540-5	8.9	91
195	Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. <i>Strahlentherapie Und Onkologie</i> , 2012 , 188, 334-9	4.3	91
194	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. <i>Neuro-Oncology</i> , 2016 , 18, 1529-1537	1	80
193	Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis. <i>NeuroImage: Clinical</i> , 2018 , 20, 537-542	5.3	79
192	Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. <i>Clinical Cancer Research</i> , 2016 , 22, 2190-6	12.9	78
191	NIMG-46. IMPACT OF FET PET ON MULTIDISCIPLINARY NEUROONCOLOGICAL TUMOR BOARD DECISIONS IN PATIENTS WITH BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019 , 21, vi171-vi172	1	78
190	QOLP-20. QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi218-vi219	1	78
189	PET/MRI Radiomics in Patients With Brain Metastases. <i>Frontiers in Neurology</i> , 2020 , 11, 1	4.1	77
188	Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 84-92	8.8	77
187	The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. <i>NeuroImage: Clinical</i> , 2017 , 13, 386-394	5.3	76
186	Static and dynamic F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 443-451	8.8	73
185	PET imaging in patients with brain metastasis-report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019 , 21, 585-595	1	72
184	Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2011 , 99, 218-24	5.3	71
183	Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. <i>Neuro-Oncology</i> , 2017 , 19, 281-288	1	69
182	Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. <i>European Radiology</i> , 2015 , 25, 3017-24	8	65
181	Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase F-FET PET accuracy without dynamic scans. <i>European Radiology</i> , 2017 , 27, 2916-2927	8	62
180	Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. <i>Human Gene Therapy</i> , 2003 , 14, 277-97	4.8	61
179	[11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. <i>Journal of Neuro-Oncology</i> , 2010 , 96, 231-9	4.8	59

178	Diagnostic challenges in meningioma. <i>Neuro-Oncology</i> , 2017 , 19, 1588-1598	1	57
177	Predicting IDH genotype in gliomas using FET PET radiomics. <i>Scientific Reports</i> , 2018 , 8, 13328	4.9	56
176	Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[F]fluoroethyl)-L-tyrosine (FET). <i>Methods</i> , 2017 , 130, 124-134	4.6	55
175	Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. <i>Neuro-Oncology</i> , 2016 , 18, 1462-4	1	52
174	Current status of PET imaging in neuro-oncology. <i>Neuro-Oncology Advances</i> , 2019 , 1, vdz010	0.9	51
173	The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 88-92	8.9	47
172	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 744-51	1	46
171	Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 905-15	8.8	45
170	Amino acid PET and MR perfusion imaging in brain tumours. <i>Clinical and Translational Imaging</i> , 2017 , 5, 209-223	2	43
169	Early electroencephalography in acute ischemic stroke: prediction of a malignant course?. <i>Clinical Neurology and Neurosurgery</i> , 2007 , 109, 45-9	2	43
168	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020 , 22, 17-30	1	43
167	Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature. <i>Radiation Oncology</i> , 2013 , 8, 52	4.2	41
166	Comparison of F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2257-2265	8.8	41
165	Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with Glioblastoma. <i>Molecular Imaging</i> , 2010 , 9, 7290.2010.00002	3.7	40
164	Deep brain stimulation of the subthalamic nucleus reversibly deteriorates stuttering in advanced Parkinson's disease. <i>Journal of Neural Transmission</i> , 2006 , 113, 625-31	4.3	40
163	The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1217-22	8.9	38
162	Radiomics in neuro-oncology: Basics, workflow, and applications. <i>Methods</i> , 2021 , 188, 112-121	4.6	38
161	Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation. <i>Journal of Neurology</i> , 2013 , 260, 1367-74	5.5	36

160	Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by 18F-Fluoroethyl-L-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 129-137	8.9	34
159	FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 591-602	8.8	34
158	Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-18F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging. <i>Molecular Imaging</i> , 2013 , 12, 7290.2013.00051	3.7	33
157	Suspected new-onset autoimmune temporal lobe epilepsy with amygdala enlargement. <i>Epilepsia</i> , 2016 , 57, 1485-94	6.4	33
156	Pseudoprogression after glioma therapy: an update. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 1109-1115	4.3	32
155	Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?. <i>Frontiers in Neurology</i> , 2016 , 7, 120	4.1	32
154	Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 2377-2386	8.8	31
153	Extracranial Metastases of a Cerebral Glioblastoma: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2018 , 11, 591-600	1	31
152	The severity of ischemia determines and predicts malignant brain edema in patients with large middle cerebral artery infarction. <i>Cerebrovascular Diseases</i> , 2012 , 33, 1-7	3.2	30
151	Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 615-23	4.8	29
150	F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 584-589	8.9	29
149	Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1889-1901	8.8	28
148	5-Aminolevulinic Acid and (18)F-FET-PET as Metabolic Imaging Tools for Surgery of a Recurrent Skull Base Meningioma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2013 , 74, 211-6	1.5	28
147	Ocular flutter, generalized myoclonus, and trunk ataxia associated with anti-GQ1b antibodies. <i>Archives of Neurology</i> , 2008 , 65, 659-61		26
146	FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation. <i>Cancers</i> , 2020 , 12,	6.6	26
145	Volumetry of [11C]-Methionine Positron Emission Tomographic Uptake as a Prognostic Marker before Treatment of Patients with Malignant Glioma. <i>Molecular Imaging</i> , 2012 , 11, 7290.2012.00022	3.7	24
144	Volumetry of [11C]-methionine positron emission tomographic uptake as a prognostic marker before treatment of patients with malignant glioma. <i>Molecular Imaging</i> , 2012 , 11, 516-27	3.7	24
143	Influence of Bevacizumab on Blood-Brain Barrier Permeability and -(2-F-Fluoroethyl)-L-Tyrosine Uptake in Rat Gliomas. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 700-705	8.9	23

142	Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients. <i>Cancers</i> , 2019 , 11,	6.6	23
141	Immunoabsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. <i>European Neurology</i> , 2011 , 66, 183-9	2.1	23
140	Prognostic value of 18F-FDG PET in monosegmental stenosis and myelopathy of the cervical spinal cord. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1385-91	8.9	23
139	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021 , 23, 881-893	1	23
138	Imaging of Non-Br Very Subtle Contrast-Enhancing Malignant Gliomas with [11C]-Methionine Positron Emission Tomography. <i>Molecular Imaging</i> , 2011 , 10, 7290.2011.00014	3.7	22
137	Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. <i>Radiation Oncology</i> , 2016 , 11, 87	4.2	22
136	F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 505-511	8.9	22
135	Update on amino acid PET of brain tumours. <i>Current Opinion in Neurology</i> , 2018 , 31, 354-361	7.1	22
134	Applications of radiomics and machine learning for radiotherapy of malignant brain tumors. <i>Strahlentherapie Und Onkologie</i> , 2020 , 196, 856-867	4.3	21
133	Comparison of O-(2-F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study. <i>World Neurosurgery</i> , 2018 , 113, e727-e737	2.1	21
132	Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma. <i>Radiation Oncology</i> , 2019 , 14, 73	4.2	20
131	Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	20
130	Clinical value of O-(2-[(18F)-fluoroethyl]-L-tyrosine positron emission tomography in patients with low-grade glioma. <i>Neurosurgical Focus</i> , 2013 , 34, E3	4.2	20
129	[18F]FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas. <i>Molecular Imaging and Biology</i> , 2011 , 13, 547-557	3.8	20
128	Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. <i>Molecular Imaging</i> , 2010 , 9, 40-6	3.7	20
127	Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients. <i>Neuro-Oncology</i> , 2019 , 21, 1331-1338	1	19
126	Spatial Relationship of Glioma Volume Derived from F-FET PET and Volumetric MR Spectroscopy Imaging: A Hybrid PET/MRI Study. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 603-609	8.9	19
125	Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region. <i>Neuro-Oncology</i> , 2013 , 15, 1721-31	1	19

124	Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 459-67	8.8	18
123	Influence of blood-brain barrier permeability on O-(2-F-fluoroethyl)-L-tyrosine uptake in rat gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 408-416	8.8	18
122	Selective immune adsorption treatment of severe Guillain Barré syndrome in the intensive care unit. <i>Neurocritical Care</i> , 2009 , 11, 317-21	3.3	18
121	Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake in cerebral gliomas. <i>Nuclear Medicine Communications</i> , 2014 , 35, 245-51	1.6	17
120	Earlier diagnosis of progressive disease during bevacizumab treatment using O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography in comparison with magnetic resonance imaging. <i>Molecular Imaging</i> , 2013 , 12, 273-6	3.7	17
119	O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. <i>Neuro-Oncology</i> , 2017 , 19, 1271-1278	1	16
118	Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1444-1453	21.7	16
117	Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors. <i>Molecules</i> , 2020 , 25,	4.8	15
116	Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 1115-23	8.8	15
115	The Treatment of Gliomas in Adulthood. <i>Deutsches A&#x0308;rzteblatt International</i> , 2018 , 115, 356-364	2.5	15
114	Letter to the Editor: "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460]. <i>Journal of Neuro-Oncology</i> , 2014 , 120, 665-6	4.8	15
113	Hypermetabolism in 18F-FDG PET predicts favorable outcome following decompressive surgery in patients with degenerative cervical myelopathy. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1577-83	8.9	15
112	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. <i>Oncotarget</i> , 2016 , 7, 82028-82045	3.3	15
111	Rapid geographical clustering of wound botulism in Germany after subcutaneous and intramuscular injection of heroin. <i>Neurocritical Care</i> , 2007 , 6, 30-4	3.3	14
110	Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET. <i>Clinical Nuclear Medicine</i> , 2018 , 43, 895-898	1.7	14
109	Monitoring of Radiochemotherapy in Patients with Glioblastoma Using O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography: Is Dynamic Imaging Helpful?. <i>Molecular Imaging</i> , 2013 , 12, 7290.2013.00056	3.7	13
108	Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. <i>Journal of Neuro-Oncology</i> , 2009 , 93, 425-30	4.8	13
107	Sequential escalation of therapy in "malignant" cerebral venous and sinus thrombosis. <i>Neurocritical Care</i> , 2010 , 12, 98-102	3.3	13

106	Evaluation of factors influencing F-FET uptake in the brain. <i>NeuroImage: Clinical</i> , 2018 , 17, 491-497	5.3	13
105	Imaging of non- or very subtle contrast-enhancing malignant gliomas with [¹¹ C]-methionine positron emission tomography. <i>Molecular Imaging</i> , 2011 , 10, 453-9	3.7	13
104	Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 1626-1635	8.8	12
103	Reply to "[¹⁸ F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al. <i>Neuro-Oncology</i> , 2013 , 15, 816-7	1	12
102	Radiomics derived from amino-acid PET and conventional MRI in patients with high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 62, 272-280	1.4	12
101	Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2019 , 9, 84	5.3	11
100	O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine PET in gliomas: influence of data processing in different centres. <i>EJNMMI Research</i> , 2017 , 7, 64	3.6	11
99	¹¹ C-Methionine Positron Emission Tomographic Imaging of Biologic Activity of a Recurrent Glioblastoma Treated with Stereotaxy-Guided Laser-Induced Interstitial Thermotherapy. <i>Molecular Imaging</i> , 2012 , 11, 7290.2011.00046	3.7	11
98	Discrepant MR and [(¹⁸ F)Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure. <i>Case Reports in Oncology</i> , 2012 , 5, 490-4	1	11
97	¹¹ C-flumazenil positron emission tomography demonstrates reduction of both global and local cerebral benzodiazepine receptor binding in a patient with Stiff Person Syndrome. <i>Journal of Neurology</i> , 2008 , 255, 1361-4	5.5	11
96	A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma. <i>Cancers</i> , 2020 , 12,	6.6	11
95	Use of PET Imaging in Neuro-Oncological Surgery. <i>Cancers</i> , 2021 , 13,	6.6	11
94	Current trends in the use of O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine ([¹⁸ F]FET) in neurooncology. <i>Nuclear Medicine and Biology</i> , 2021 , 92, 78-84	2.1	11
93	Feasibility, Risk Profile and Diagnostic Yield of Stereotactic Biopsy in Children and Young Adults with Brain Lesions. <i>Klinische Padiatrie</i> , 2017 , 229, 133-141	0.9	10
92	"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. <i>Journal of Neuro-Oncology</i> , 2013 , 112, 209-15	4.8	10
91	Posthypoxic myoclonus (Lance-Adams syndrome) treated with lacosamide. <i>Clinical Neuropharmacology</i> , 2010 , 33, 216-7	1.4	10
90	A giant bilateral calcified chronic subdural hematoma. <i>Neurocritical Care</i> , 2010 , 12, 272-3	3.3	10
89	Multitracer PET imaging in Heidenhain variant of Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> , 2006 , 253, 258-60	5.5	10

88	Treatment Monitoring of Immunotherapy and Targeted Therapy Using F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 464-470	8.9	10
87	Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?. <i>Molecular Imaging</i> , 2013 , 12, 388-95	3.7	10
86	Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 1486-1495	8.8	9
85	Clinical routine assessment of palliative care symptoms and concerns and caregiver burden in glioblastoma patients: an explorative field study. <i>Journal of Neuro-Oncology</i> , 2018 , 138, 321-333	4.8	9
84	Isomers of 4-[¹⁸ F]fluoro-proline: radiosynthesis, biological evaluation and results in humans using PET. <i>Current Radiopharmaceuticals</i> , 2014 , 7, 123-32	1.8	9
83	AIDS-Related Central Nervous System Toxoplasmosis With Increased ¹⁸ F-Fluoroethyl-L-Tyrosine Amino Acid PET Uptake Due to LAT1/2 Expression of Inflammatory Cells. <i>Clinical Nuclear Medicine</i> , 2017 , 42, e506-e508	1.7	8
82	Early Treatment Response Assessment Using F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 918-925	8.9	8
81	Role of the default mode resting-state network for cognitive functioning in malignant glioma patients following multimodal treatment. <i>NeuroImage: Clinical</i> , 2020 , 27, 102287	5.3	8
80	Influence of Dexamethasone on O-(2-[¹⁸ F]fluoroethyl)-L-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake. <i>Molecular Imaging and Biology</i> , 2019 , 21, 168-174	3.8	8
79	Detection of remote neuronal reactions in the Thalamus and Hippocampus induced by rat glioma using the PET tracer cis-4-[¹⁸ F]fluoro-D-proline. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013 , 33, 724-31	7.3	8
78	Systemic thrombolysis with rt-PA in patients under 40 years of age: a subgroup analysis of the Cologne Stroke Experience. <i>Cerebrovascular Diseases</i> , 2010 , 30, 514-8	3.2	8
77	A rare differential diagnosis in dysphagia: wound botulism. <i>Laryngoscope</i> , 2006 , 116, 831-2	3.6	8
76	¹¹ C-Methionine positron emission tomographic imaging of biologic activity of a recurrent glioblastoma treated with stereotaxy-guided laser-induced interstitial thermotherapy. <i>Molecular Imaging</i> , 2012 , 11, 265-71	3.7	8
75	Diagnostic impact of additional O-(2-[¹⁸ F]fluoroethyl)-L-tyrosine (F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients. <i>British Journal of Neurosurgery</i> , 2019 , 1-7	1	7
74	Interesting image. PET imaging of a butterfly glioblastoma. <i>Clinical Nuclear Medicine</i> , 2010 , 35, 49-50	1.7	7
73	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2001-2001	2.2	7
72	Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 9-15	3.5	7
71	Loss of H3K27me3 in meningiomas. <i>Neuro-Oncology</i> , 2021 , 23, 1282-1291	1	7

70	Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[F]fluoroethyl)-L-tyrosine PET. <i>Clinical Lung Cancer</i> , 2019 , 20, e148-e151	4.9	7
69	Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI. <i>Neuro-Oncology Advances</i> , 2019 , 1, vdz038	0.9	6
68	Clinical value of 2-deoxy-[18F]fluoro-D-glucose positron emission tomography in patients with cervical spondylotic myelopathy. <i>Neurosurgical Focus</i> , 2013 , 35, E2	4.2	6
67	The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord. <i>Neuro-Oncology</i> , 2017 , 19, 710-718	1	6
66	Comparison of [F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study. <i>Molecular Imaging and Biology</i> , 2020 , 22, 198-207	3.8	6
65	Sequential implementation of DSC-MR perfusion and dynamic [F]FET PET allows efficient differentiation of glioma progression from treatment-related changes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 1956-1965	8.8	6
64	FET PET in Primary Central Nervous System Vasculitis. <i>Clinical Nuclear Medicine</i> , 2018 , 43, e322-e323	1.7	6
63	The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 62, 267-271	1.4	6
62	Comment on "Hypometabolic gliomas on FET-PET-is there an inverted U-curve for survival?". <i>Neuro-Oncology</i> , 2019 , 21, 1612-1613	1	5
61	Flare Phenomenon in -(2-F-Fluoroethyl)-l-Tyrosine PET After Resection of Gliomas. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1294-1299	8.9	5
60	Investigational PET tracers for high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 62, 281-294	1.4	5
59	Functional magnetic resonance imaging in glioma patients: from clinical applications to future perspectives. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 62, 295-302	1.4	5
58	Treatment-Related Uptake of -(2-F-Fluoroethyl)-l-Tyrosine and l-[Methyl-H]-Methionine After Tumor Resection in Rat Glioma Models. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 1373-1379	8.9	4
57	Investigation of cis-4-[F]Fluoro-D-Proline Uptake in Human Brain Tumors After Multimodal Treatment. <i>Molecular Imaging and Biology</i> , 2018 , 20, 1035-1043	3.8	4
56	Photopenic Defects in Gliomas With Amino-Acid PET and Relative Prognostic Value: A Multicentric 11C-Methionine and 18F-FDOPA PET Experience. <i>Clinical Nuclear Medicine</i> , 2021 , 46, e36-e37	1.7	4
55	Feature-based PET/MRI radiomics in patients with brain tumors. <i>Neuro-Oncology Advances</i> , 2020 , 2, iv15-iv21	1.9	4
54	Effect of Zolpidem in the Aftermath of Traumatic Brain Injury: An MEG Study. <i>Case Reports in Neurological Medicine</i> , 2020 , 2020, 8597062	0.7	4
53	Evaluation of FET PET Radiomics Feature Repeatability in Glioma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4

52	Radiomics for the non-invasive prediction of the BRAF mutation status in patients with melanoma brain metastases.. <i>Neuro-Oncology</i> , 2021 ,	1	4
51	Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma. <i>World Neurosurgery</i> , 2019 , 127, 213-215	2.1	3
50	Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine. <i>Case Reports in Oncology</i> , 2020 , 13, 35-42	1	3
49	NIMG-32. DIFFERENTIATION OF PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS BASED ON FET PET RADIOMICS. <i>Neuro-Oncology</i> , 2017 , 19, vi148-vi149	1	3
48	Coma and cerebral imaging. <i>SpringerPlus</i> , 2015 , 4, 180		3
47	Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. <i>Clinical Cancer Research</i> , 2021 , 27, 3704-3713	12.9	3
46	Correlation of Dynamic O-(2-[F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography, Conventional Magnetic Resonance Imaging, and Whole-Brain Histopathology in a Pretreated Glioblastoma: A Postmortem Study. <i>World Neurosurgery</i> , 2018 , 119, e653-e660	2.1	3
45	Histogram analysis reveals a better delineation of tumor volume from background in 18F-FET PET compared to CBV maps in a hybrid PET/MR studie in gliomas. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2014 , 734, 175-178	1.2	2
44	Pitfalls in der [18F]-FET-PET-Diagnostik von Hirntumoren. <i>Chinese Journal of Polymer Science (English Edition)</i> , 2015 , 38, 295-303	0.1	2
43	Treatment monitoring of immunotherapy and targeted therapy using FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13525-e13525	2.2	2
42	Positron-Emission-Tomography in Diffuse Low-Grade Gliomas 2017 , 263-286		2
41	F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection. <i>Journal of Neuro-Oncology</i> , 2021 , 155, 71-80	4.8	2
40	Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 ,	8.8	2
39	MRI Follow-up of Astrocytoma: Automated Coregistration and Color-Coding of FLAIR Sequences Improves Diagnostic Accuracy With Comparable Reading Time. <i>Journal of Magnetic Resonance Imaging</i> , 2020 , 52, 1197-1206	5.6	1
38	Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 501-509	4.8	1
37	Reply: discriminating ability of (18)F-FET PET for several cerebral neoplastic lesions. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 176	8.9	1
36	PET Imaging of Brain Tumors. <i>Medical Radiology</i> , 2013 , 121-134	0.2	1
35	Thoracic disc herniation with affection of the anterior spinothalamic tract: a case report and review of literature. <i>Neurology India</i> , 2011 , 59, 627-8	0.7	1

34	Traction lesion of the brachial plexus during bodyflying. <i>Journal of Neurology</i> , 2010 , 257, 851-2	5.5	1
33	Diagnostic value of the electromyography of the extraocular muscles. <i>Clinical Neurophysiology</i> , 2008 , 119, 2785-8	4.3	1
32	FET and FDOPA PET Imaging in Glioma 2020 , 211-221		1
31	Advantages and limitations of amino acid PET for tracking therapy response in glioma patients. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 137-146	4.3	1
30	Reply: Flare Phenomenon in -(2-[F]-Fluoroethyl)-L-Tyrosine PET After Resection of Gliomas. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1852	8.9	1
29	Lesion-Function Analysis from Multimodal Imaging and Normative Brain Atlases for Prediction of Cognitive Deficits in Glioma Patients. <i>Cancers</i> , 2021 , 13,	6.6	1
28	Reply to the letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation. <i>Neuro-Oncology</i> , 2021 , 23, 1410-1411	1	1
27	Letter to the Editor: "Comparing the Volume of Brain Metastases in F-18-FET-PET and MRI". <i>World Neurosurgery</i> , 2016 , 89, 722	2.1	1
26	NIMG-05. THE T2-FLAIR MISMATCH SIGN IN IDH-MUTANT ASTROCYTOMAS - IS THERE AN ASSOCIATION WITH FET PET UPTAKE?. <i>Neuro-Oncology</i> , 2019 , 21, vi162-vi162	1	1
25	Dynamic FET PET Imaging of a "Butterfly" IDH-Wildtype Anaplastic Astrocytoma. <i>Clinical Nuclear Medicine</i> , 2019 , 44, e581-e582	1.7	1
24	Cis-4-[18F]fluoro-D-proline detects neurodegeneration in patients with akinetic-rigid parkinsonism. <i>Nuclear Medicine Communications</i> , 2019 , 40, 383-387	1.6	1
23	Combined F-FET PET and diffusion kurtosis MRI in posttreatment glioblastoma: differentiation of true progression from treatment-related changes. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab044	0.9	1
22	Use of advanced neuroimaging and artificial intelligence in meningiomas.. <i>Brain Pathology</i> , 2022 , 32, e13015	6	1
21	Radiomics outperforms semantic features for prediction of response to stereotactic radiosurgery in brain metastases. <i>Radiotherapy and Oncology</i> , 2021 , 166, 37-43	5.3	0
20	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. <i>Neuro-Oncology</i> , 2021 , 23, vi126-vi127	1	0
19	Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement. <i>Scientific Reports</i> , 2021 , 11, 20828	4.9	0
18	A Linearized Fit Model for Robust Shape Parameterization of FET-PET TACs. <i>IEEE Transactions on Medical Imaging</i> , 2021 , 40, 1852-1862	11.7	0
17	Adapting MR-BrainPET scans for comparison with conventional PET: experiences with dynamic FET-PET in brain tumours. <i>EJNMMI Physics</i> , 2014 , 1, A64	4.4	

16	Rezidivdiagnostik bei Hirntumoren 2017 , 32, 312-316	0.2
15	Sensitivity of intraoperative 5-aminolevulinic acid fluorescence compared with PET using O-(2- 18 F-fluoroethyl)-L-tyrosine to detect cerebral gliomas. <i>Neurological Research</i> , 2013 , 35, 329-30	2.7
14	NIMG-26. DIAGNOSIS OF PSEUDOPROGRESSION FOLLOWING RADIOTHERAPY PLUS LOMUSTINE-TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS USING FET PET. <i>Neuro-Oncology</i> , 2020 , 22, ii152-ii153	1
13	NIMG-14. MACHINE LEARNING-BASED EVALUATION OF STATIC AND DYNAMIC FET-PET FOR THE DETECTION OF PSEUDOPROGRESSION IN PATIENTS WITH IDH-WILDTYPE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020 , 22, ii149-ii150	1
12	NIMG-43. IMAGING FINDINGS FOLLOWING REGORAFENIB IN PATIENTS WITH MALIGNANT GLIOMA: FET PET ADDS VALUABLE INFORMATION TO ANATOMICAL MRI. <i>Neuro-Oncology</i> , 2020 , 22, ii157-ii157	1
11	The Role of Radionuclide Diagnostic Methods in Neuro-Oncology. <i>Vestnik Rentgenologii I Radiologii</i> , 2020 , 101, 221-234	0.3
10	NIMG-27. REGORAFENIB RESPONSE ASSESSMENT USING FET PET IN PATIENTS WITH PROGRESSIVE GLIOMA. <i>Neuro-Oncology</i> , 2021 , 23, vi134-vi134	1
9	Case Report: Detection of Symptomatic Treatment-Related Changes in a Patient With Anaplastic Oligodendroglioma Using FET PET. <i>Frontiers in Oncology</i> , 2021 , 11, 735388	5.3
8	NIMG-06. CHARACTERIZATION OF LONG-TERM METABOLIC CHANGES OF IRRADIATED BRAIN METASTASES USING SERIAL DYNAMIC FET PET IMAGING. <i>Neuro-Oncology</i> , 2021 , 23, vi128-vi128	1
7	NIMG-20. DIFFERENTIATION OF TREATMENT-RELATED CHANGES FROM TUMOR PROGRESSION FOLLOWING BRACHYTHERAPY IN PATIENTS WITH WHO II AND III GLIOMAS USING FET PET. <i>Neuro-Oncology</i> , 2021 , 23, vi132-vi132	1
6	Survival effects of a strategy favoring second-line multimodal treatment compared to supportive care in glioblastoma patients at first progression. <i>Journal of Neurosurgery</i> , 2018 , 1-6	3.2
5	Metabolic Imaging of Brain Metastasis 2020 , 159-171	
4	Positron Emission Tomography in Diffuse Low-Grade Gliomas 2013 , 235-248	
3	Combined FET PET/ADC mapping: improved imaging of glioma infiltration?. <i>Neuro-Oncology</i> , 2020 , 22, 313-314	1
2	Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18 F-FDG PET/CT in differentiating brain tumor progression from radiation injury. <i>Neuro-Oncology</i> , 2017 , 19, 300-301	1
1	Imaging of Response to Radiosurgery and Immunotherapy in Brain Metastases: Quo Vadis?. <i>Current Treatment Options in Neurology</i> , 2021 , 23, 1	4.4